Tuesday, November 26, 2013

Gene Choices & Choice Genes

The United States Patent and Trademark Office ("USPTO") issued United States Patent Number 8,543,339 to 23andMe, Inc. on September 24, 2013.  The patent is entitled "Gamete Donor Selection Based On Genetic Calculations."  Here is the abstract:
Gamete donor selection includes receiving a specification including a phenotype of interest, receiving a genotype of a recipient and a plurality of genotypes of a respective plurality of donors, determining statistical information pertaining to the phenotype of interest based at least in part on different pairings of the genotype of the recipient and a genotype of a donor in the plurality of donors, and identifying a preferred donor among the plurality of donors, based at least in part on the statistical information determined.
Here is Claim 1 of the patent, as issued by the USPTO:
A system for gamete donor selection comprising: one or more processors configured to: receive a specification including a phenotype of interest that can be present in a hypothetical offspring; receive a genotype of a recipient and a plurality of genotypes of a respective plurality of donors; determine statistical information including probabilities of observing the phenotype of interest resulting from different combinations of the genotype of the recipient and genotypes of the plurality of donors; and identify a preferred donor among the plurality of donors, based at least in part on an evaluation of the statistical information determined, including: to compare the probabilities of observing the phenotype of interest resulting from different combinations of the genotype of the recipient and the genotypes of the plurality of donors to identify the preferred donor; and a memory coupled to the processor, configured to provide the processor with instructions.
Assuming that 23andMe develops this concept into a commercial service, choosing the genetic traits of one's baby may soon be as easy as a few mouse-clicks and the swipe of a credit card.  As I suggested in a 2008 article entitled "Patenting Human Evolution" (freely available here) and a 2009 article entitled "Open and Proprietary Biological Innovation in Human Genetic Enhancement" (freely available here), patents may soon be a selective force that helps drive human evolution.  Perhaps this patent is a harbinger. 

Monday, November 25, 2013

23andFDA

Knowledge of the human genome promises much to humanity.  One common suggestion is that sequencing a person's genome will unlock powerful opportunities for diagnosis and therapy.  A leader in the commercial market for human genomics is Google's neighbor, 23andMe, Inc., of Mountain View, California.  It fashions itself "The leading health and ancestry DNA service."  The Food and Drug Administration ("FDA") appears to think that 23andme has moved its services into the market prematurely.  In a "WARNING LETTER" sent to the company on November 22, 2013, the FDA states that it has yet to approve 23andme's product, which the agency characterizes as
a device within the meaning of section 201(h) of the [Food, Drug and Cosmetic] Act ["FDCA"], 21 U.S.C. 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or is intended to affect the structure or function of the body.
In its letter, the FDA orders 23andme to take its product off the market immediately:
23andMe must immediately discontinue marketing the PGS until such time as it receives FDA marketing authorization for the device. The PGS is in class III under section 513(f) of the FD&C Act, 21 U.S.C. 360c(f). Because there is no approved application for premarket approval in effect pursuant to section 515(a) of the FD&C Act, 21 U.S.C. 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the FD&C Act, 21 U.S.C. 360j(g), the PGS is adulterated under section 501(f)(1)(B) of the FD&C Act, 21 U.S.C. 351(f)(1)(B).  Additionally, the PGS is misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because notice or other information respecting the device was not provided to FDA as required by section 510(k) of the Act, 21 U.S.C. § 360(k).
This federal regulatory enforcement action is sure to galvanize the human genomics industry into action.  One possibility is to spur efforts to comply better with the FDCA.  Another is that 23andme will challenge the FDA's allegations, perhaps by disputing whether the FDCA does, in fact, apply to genomics testing.  It is not a foregone conclusion that the federal courts will side with the FDA, even though they do tend to give federal agency decisions considerable deference.

Regardless of the outcome of this particular FDA enforcement action, human genomics is certain to play an acceleratingly-important role in human health.  As the avid Tudorian, Allison Plowden, once wrote, "The laws of genetics apply even if you refuse to learn them."

Tuesday, November 12, 2013

E Pluribus Verbi

Too many cooks may spoil the broth, but how many authors are too many when collaborating to write an article?  To explore this quandry, my colleagues, Bill Tomlinson (University of California, Irvine), Joel Ross (University of Puget Sound), Paul Andre (Carnegie Mellon University), Eric P. S. Baumer (Cornell University), Donald J. Patterson (University of California, Irvine), Joseph Corneli (Independent), Martin Mahaux (Independent), Syavash Nobarany (University of British Columbia), Nithya Sambasivan (Independent), Marco Lazzari (University of Bergamo), Birgit Penzenstadler (Technische Universität München), David J. Callele (Independent), Gary M Olson (University of California, Irvine), M. Six Silberman (Independent), Marcus Ständer (Darmstadt University of Technology), Fabio Romancini Palamedi (Independent), Albert Ali Salah (Boğaziçi University), Eric Morrill (Independent), Xavier Franch (University of Puget Sound), Florian 'Floyd' Mueller (Independent), Joseph 'Jofish' Kaye (Independent), Rebecca W. Black (University of California, Irvine), Marisa L. Cohn (University of California, Irvine), Patrick C. Shih (University of California, Irvine), Johanna Brewer (Independent), Nitesh Yashbir Goyal (Independent), Pirjo Näkki (VTT Technical Research Centre of Finland), Jeff Huang (Independent), Nilufar Baghaei (Independent), and Craig Saper (The Hilltop Institute at UMBC), and I collaboratively coauthored an article entitled "Massively Distributed Authorship of Academic Papers" that was published on February 17, 2013, in ACM Conference on Human Factors in Computing Systems (CHI 2012) Extended Abstracts (alt.chi).  Here is the abstract:
Wiki-like or crowdsourcing models of collaboration can provide a number of benefits to academic work. These techniques may engage expertise from different disciplines, and potentially increase productivity. This paper presents a model of massively distributed collaborative authorship of academic papers. This model, developed by a collective of 31 authors, identifies key tools and techniques that would be necessary or useful to the writing process. The process of collaboratively writing this paper was used to discover, negotiate, and document issues in massively authored scholarship. Our work provides the first extensive discussion of the experiential aspects of large-scale collaborative research.
Our full article is available for free download on SSRN.  Thank you very much to all of my talented and cooperative coauthors who made this experiment in collaborative writing a pleasure.  Bill Tomlinson deserves massive and special praise for deftly coordinating the creation of the article.

Wednesday, November 6, 2013

Medtronic v. Boston Scientific

On November 5, 2013, the United States Supreme Court heard oral arguments in Medtronic, Inc. v. Boston Scientific Corporation, et al..  Seth Waxman, a former U.S. Solicitor General, attorney for petitioner, Medtronic, and partner at WilmerHale, explained the legal issue at the heart of the litigation:
Patent law places the burden of proving infringement on the patentee. And until this case, it was settled that the burden does not shift if the issue arises in a declaratory action seeking a judgment of non-infringement.  The [Court of Appeals for the] Federal Circuit imposed a different rule in suits brought under [MedImmune, Inc v. Genentech, Inc., et al.] where the party seeking a declaration of non-infringement is a licensee. That was error.

Allocation of the burden of proof inheres in the governing substantive law while the Declaratory Judgment Act is procedural only and does not change substantive rights. The burden of proof in MedImmune actions, like all other declaratory actions, remains where it would have rested in the equivalent coercive suit brought by that patentee.
Based on what transpired in these oral arguments, the Supreme Court appears skeptical of the burden-shifting rule introduced by the Federal Circuit in MedImmune.  A decision is likely before next summer.

Tuesday, November 5, 2013

Toronto Mayor Cracks Under Pressure

Rob Ford became mayor of Toronto, Canada, on December 1, 2010.  On November 5, 2013, he made a stunning (though not unexpected) admission:
Question: Do you smoke crack cocaine?
Ford: Yes I have smoked crack cocaine. But no, do I, am I am addict? No. Have I tried it? Probably in one of my drunken stupors, probably approximately about a year ago. I answered your question. You ask the question properly, I’ll answer it. Yes, I’ve made mistakes. All I can do now is apologize and move on.
Ford's tenure as mayor of Toronto has been nasty and brutish, and his abuse of alcohol and use of crack will likely make it short as well.  Like a clock inexorably counting down the last few seconds of one of his beloved football games, his time is almost up.  His resignation is likely just days, or possibly even mere hours, away.  What a tawdry affair in an otherwise good city.

Thursday, October 31, 2013

Red Sox Ascend Olympus

Former Commissioner of Major League Baseball (not to mention former President of Yale University) Bart Giamatti paid tribute to Fenway Park as follows:
As I grew up, I knew that as a building [Fenway Park] was on the level of Mount Olympus, the Pyramid at Giza, the nation's capitol, the czar's Winter Palace, and the Louvre — except, of course, that is better than all those inconsequential places.

By winning the World Series on October 30, 2013 - the team's third World Series championship in a decade - the Boston Red Sox have lived up to Giamatti's Olympian tribute.  What a great time to be a Red Sox fan!

Wednesday, October 30, 2013

Roger Daltrey Fêtes Winston Churchill

Roger Daltrey helped politicians and distinguished guests celebrate the unveiling of a statue of Winston Churchill today on Capitol Hill. Daltrey began with Ben E. King's "Stand By Me" (starting at 40:30 on the video) to celebrate the trans-Atlantic alliance that Churchill helped forge. Rather cheekily, as politicians such as John Boehner, John Kerry, Mitch McConnell, and Nancy Pelosi were still present, the Who's outspoken lead singer closed the ceremony with "Won't Get Fooled Again" (starting at 54:07 on the video).

Lies, Damn Lies, And Statistics

The rise of empirical methods is one of the most marked recent trends in the legal academy.  Data-driven scholarship is transforming fields as diverse as intellectual property, criminal law, and environmental law.  Professor Dan Kahan, of Yale Law School, is a leader in the empirical study of law.  In an October 23, 2013, article, entitled "Statistical Fluke? Researcher's Observations on Tea Party and Science Spark Political Frenzy," Science Magazine discussed recent research by Kahan discussing correlations between political beliefs and scientific knowledge.  As the article points out,
It started innocently on 15 October. On his blog, Kahan posted an informal analysis of survey data that compares people’s comprehension of scientific concepts and their political outlook. The data were gathered from a large U.S. study of how people perceive the risk of vaccination. And when Kahan crunched the numbers, they revealed a small correlation between science comprehension and political leaning. One finding: Those who identified themselves as “liberal” tended to have greater scientific comprehension than those who self-identified as “conservative.”
This finding set the innumerate cat among the credulous pigeons.  One of the article's central insights is that statistical analysis continues to defy competent interpretation by many people, including those who should know better.  More than a century after Mark Twain attributed the phrase to Benjamin Disraeli, widespread incomprehension of statistical analysis lends credence to the observation that "There are three kinds of lies: lies, damned lies, and statistics."

Tuesday, October 29, 2013

Hacking Genomes

Yaniv Erlich, a bioinformaticist at the Whitehead Institute, announced on October 24, 2013, that he and his colleagues had assembled a family tree made up of 13 million people.  The genomic data used to analyze this massive family tree came from a genomics services provider called www.geni.com.  Here is an excerpt from an article in Nature about Erlich's research project:
Using data pulled from online genealogy sites, a renowned ‘genome hacker’ has constructed what is likely the biggest family trees ever assembled. The researcher and his team now plan to use the data — including a single uber-pedigree comprising 13 million individuals, which stretches back to the 15th century — to analyse the inheritance of complex genetic traits, such as longevity and facial features.
 George Burns once said "Happiness is having a large, loving, caring, close-knit family in another city."  For the huge family Erlich has discovered, there may be few cities in which to hide.

Monday, October 28, 2013

Evil Twins Debate

Design patents are currently the hottest form of intellectual property protection.  One of the coolest institutions in the intellectual property legal academy is the University of Richmond School of Law's annual "Evil Twins Debate." This year, I am very honored to have been invited to be one of the Evil Twins in a debate entitled "Design Patents:  Great Idea, or Greatest Idea."  Purely for the sake of argument, I will represent the Greatest Idea position. Here is how the Richmond School of Law describes the Evil Twins Debate:
The Intellectual Property Institute's Evil Twin Debate Series is founded on the notion that experts are often at loggerheads on important issues of IP policy, yet remain friendly on a personal level. The series therefore brings together pairs of scholars who disagree on an important IP topic, but who can air their disagreements in a friendly exchange—serious in substance but lighthearted in tone.
2013 Debate
The Seventh Annual Evil Twin Debate will take place at noon on November 15, 2013, in the law school's moot court room. It will feature Professor Mark Janis of Indiana University's Maurer School of Law and Professor Andrew Torrance of the University of Kansas School of Law. They will debate the topic Design Patents: Great Idea, or Greatest Idea? [Emphasis added.] As always, the debate is open to the public, and a Q&A and reception will follow.
The debate will be simulcast and recorded for posting on the web.  The debate should be a lot of fun.